Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

Rhea-AI Summary

Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company focusing on extrachromosomal DNA (ecDNA) biology, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company's executives, Zachary Hornby (President and CEO) and Jami Rubin (CFO), will engage in a fireside chat session on Wednesday, September 18, 2024, at 10:20 a.m. ET in New York, NY.

Boundless Bio aims to develop transformative therapies for patients with previously intractable oncogene amplified cancers. Interested parties can access a live and archived webcast of the session through the 'Events & Presentations' section of the company's website under the Investors tab.

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will participate in the 2024 Cantor Global Healthcare Conference.

A fireside chat session is scheduled for Wednesday, September 18, 2024, in New York, NY, at 10:20 a.m. ET. A live and archived webcast of the session will be accessible under “Events & Presentations” in the Investors section of Boundless Bio’s website.

About Boundless Bio

Boundless Bio is a clinical-stage oncology company dedicated to unlocking a new paradigm in cancer therapeutics to address the significant unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Boundless Bio is developing the first ecDNA-directed therapy (ecDTx), BBI-355, which is an oral inhibitor of checkpoint kinase 1 (CHK1) being evaluated in a Phase 1/2 clinical trial in patients with oncogene amplified cancers. Boundless Bio’s second ecDTx, BBI-825, is an oral inhibitor of ribonucleotide reductase (RNR) being evaluated in a Phase 1/2 clinical trial in cancer patients with resistance gene amplifications. Leveraging its Spyglass platform, Boundless Bio has additional programs advancing through preclinical development and discovery. Boundless Bio is headquartered in San Diego, CA.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and X.

Contacts:
Ben Flaum, Boundless Bio
bflaum@boundlessbio.com

Investors
THRUST Strategic Communications
Renee Leck
renee@thrustsc.com

FAQ

When is Boundless Bio (BOLD) participating in the 2024 Cantor Global Healthcare Conference?

Boundless Bio (BOLD) is participating in the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, with a fireside chat session scheduled for 10:20 a.m. ET in New York, NY.

Who will represent Boundless Bio (BOLD) at the 2024 Cantor Global Healthcare Conference?

Zachary Hornby, President and Chief Executive Officer, and Jami Rubin, Chief Financial Officer, will represent Boundless Bio (BOLD) at the 2024 Cantor Global Healthcare Conference.

How can investors access Boundless Bio's (BOLD) presentation at the 2024 Cantor Global Healthcare Conference?

Investors can access a live and archived webcast of Boundless Bio's (BOLD) presentation under the 'Events & Presentations' section in the Investors area of the company's website.

What is the main focus of Boundless Bio's (BOLD) research and development?

Boundless Bio (BOLD) focuses on extrachromosomal DNA (ecDNA) biology to develop transformative therapies for patients with previously intractable oncogene amplified cancers.